Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

This Phase 1/2a study is testing belantamab mafodotin — an antibody-drug conjugate (a targeted drug that delivers chemotherapy directly to cancer cells) — in people with AL amyloidosis, a rare disease where abnormal proteins (light chains) are deposited in organs such as the heart, kidneys, and liver, causing damage. The drug targets a protein called BCMA found on the abnormal plasma cells that produce these light chains. The study is for people whose disease has come back or stopped responding to prior treatments. You may be eligible if: - You are 18 years of age or older - You have relapsed or refractory AL amyloidosis confirmed by biopsy - You have measurable disease based on blood or urine tests - You have had at least one prior treatment including a proteasome inhibitor, alkylator, and anti-CD38 antibody (or are not eligible for these) - Your heart function (LVEF) is above 35% and NYHA Class 1–3a - You have adequate blood counts, kidney, and liver function - Your ECOG performance status is 0, 1, or 2 You may NOT be eligible if: - You have previously been treated for active multiple myeloma - You have corneal disease (other than mild punctate keratopathy) - You are eligible for autologous stem cell transplantation - You have significant cardiovascular disease (NYHA Class 3b or 4) - You wear contact lenses (participants must not use contact lenses during the study) - You are pregnant or breastfeeding - You have had recent major surgery (within 4 weeks) - You have active infection requiring treatment Talk to your doctor to see if this trial is right for you.